slc39a9 Antibody

What is SLC39A9/ZIP9 and what are its critical functions in cellular processes?

SLC39A9, also known as ZIP9, is a multifunctional transmembrane protein with dual roles as a zinc transporter and a membrane androgen receptor. It possesses a characteristic structure with eight transmembrane domains and is primarily localized in the plasma membrane and endoplasmic reticulum . As a zinc transporter, ZIP9 facilitates the influx of zinc from extracellular space into the cytoplasm, regulating intracellular zinc homeostasis . Beyond its role in zinc transport, ZIP9 functions as a membrane androgen receptor that mediates non-classical androgen signaling pathways through G-protein coupling . This dual functionality allows ZIP9 to integrate zinc homeostasis with androgen-mediated cellular responses, particularly in processes involving cell proliferation and apoptosis.

How does the molecular structure of SLC39A9/ZIP9 relate to its experimental detection?

The human SLC39A9/ZIP9 protein consists of 307 amino acids with a calculated molecular weight of approximately 32 kDa . The protein features eight predicted transmembrane domains with extracellular C-termini . For experimental detection, researchers should be aware that while the calculated molecular weight is around 32 kDa, the observed molecular weight in laboratory conditions may vary significantly—ranging from 25 kDa to 68 kDa depending on the experimental system, post-translational modifications, and detection methods . This variability should be considered when validating antibody specificity and interpreting Western blot results. The protein's multiple transmembrane domains also present challenges for antibody epitope accessibility in certain applications, which may affect detection efficiency in native conditions.

What cellular compartments and tissue types express SLC39A9/ZIP9?

SLC39A9/ZIP9 demonstrates a diverse expression pattern across cellular compartments and tissues. At the subcellular level, ZIP9 has been identified as a resident protein in the Golgi apparatus in DT40 and HeLa cell lines . Additionally, it has been detected on cell surfaces as well as nuclear and mitochondrial membranes in human breast and prostate cancer cell lines . Regarding tissue distribution, immunohistochemical analyses have revealed variable expression patterns, with detection in human thyroid, pancreas, and placenta tissues . The protein shows differential expression levels across these tissues—thyroid tissue demonstrates notable ZIP9 expression, while pancreatic tissue exhibits lower expression levels . This broad distribution pattern underscores ZIP9's diverse physiological roles across multiple tissue types and cellular compartments.

What criteria should guide the selection of an appropriate SLC39A9/ZIP9 antibody?

When selecting an SLC39A9/ZIP9 antibody, researchers should consider multiple factors beyond basic reactivity. First, evaluate the antibody's validated applications matching your experimental needs (Western blot, immunohistochemistry, immunofluorescence, ELISA) . Second, confirm species reactivity—available antibodies show different cross-reactivity profiles with human and mouse samples being most commonly validated . Third, assess the immunogen used for antibody production; for instance, Abcam's antibody (ab272557) targets amino acids 100-200 of human SLC39A9 , while Boster's antibody (A13097-2) targets amino acids 70-120 . This information helps predict epitope accessibility in different experimental conditions. Fourth, examine published validation data, including observed molecular weights and band patterns. Finally, consider the antibody's clonality—currently available antibodies are polyclonal, which offers high sensitivity but potentially lower specificity compared to monoclonal alternatives.

What are the recommended dilution ranges and applications for different SLC39A9/ZIP9 antibodies?

These recommended dilutions serve as starting points, and optimization for specific experimental conditions is essential. For Western blot applications, antibody concentration should be adjusted based on protein loading amount and detection system sensitivity. For immunohistochemistry, antigen retrieval methods significantly impact results—Proteintech recommends TE buffer pH 9.0 or citrate buffer pH 6.0 for optimal antigen retrieval with their antibody . Researchers should perform preliminary dilution series experiments to determine optimal antibody concentrations for their specific experimental systems and sample types.

How can researchers validate the specificity of an SLC39A9/ZIP9 antibody?

Validating antibody specificity requires a systematic approach using multiple complementary methods. First, employ positive and negative controls in Western blot analysis—for example, comparing ZIP9 overexpression lysates with vector-only transfected cells, as demonstrated with Abcam's antibody showing expected band detection at approximately 32 kDa in ZIP9-overexpressing HEK293T cells but not in control lysates . Second, confirm detection in tissues known to express ZIP9 at different levels, such as thyroid (higher expression) versus pancreas (lower expression) . Third, consider gene silencing or knockout approaches to verify signal specificity. As noted in one study, "knockout of ZIP9 would lead to zi[nk homeostasis dysregulation]" , providing a valuable negative control. Fourth, peptide competition assays can confirm epitope specificity, with blocking peptides available for some antibodies . Finally, cross-validate results using multiple antibodies targeting different epitopes of ZIP9 to increase confidence in observed patterns.

How can SLC39A9/ZIP9 antibodies be used to investigate its dual function as zinc transporter and androgen receptor?

Investigating ZIP9's dual functionality requires sophisticated experimental approaches combining antibody-based detection with functional assays. For zinc transport studies, researchers can employ ZIP9 antibodies in conjunction with zinc-sensitive fluorescent probes (such as FluoZin-3) to correlate ZIP9 localization with zinc flux. This approach has revealed that ZIP9 "regulates intracellular zinc level, resulting in the enhancement of AKT1 and MAPK3/MAPK1 (Erk1/2) phosphorylation" . For androgen receptor function, co-immunoprecipitation experiments using ZIP9 antibodies can identify G-protein coupling partners—studies have demonstrated that ZIP9 couples with different G proteins, "such as the Gs protein in granulosa cells, Gi protein in cancer cells, and Gnα11 in spermatogenic cells" . Additionally, combining ZIP9 immunodetection with downstream signaling assays for MAPK3/MAPK1 phosphorylation can elucidate how it "mediates androgen-induced vascular endothelial cell proliferation through activation of an inhibitory G protein" . These integrated approaches allow researchers to distinguish between zinc-dependent and androgen-dependent functions.

What experimental strategies can differentiate between membrane and intracellular functions of SLC39A9/ZIP9?

Differentiating between membrane and intracellular ZIP9 functions requires careful subcellular fractionation combined with antibody-based detection methods. Cell surface biotinylation followed by streptavidin pull-down and immunoblotting with ZIP9 antibodies can quantify membrane-localized protein. Conversely, organelle isolation protocols can enrich Golgi membranes, where ZIP9 has been identified as "a resident protein in the Golgi in DT40 and HeLa cell lines" . For functional studies, selective permeabilization techniques allowing antibody access to either membrane or intracellular compartments can be combined with proximity ligation assays to detect interaction partners in specific cellular locations. Immunofluorescence microscopy using ZIP9 antibodies alongside organelle markers can visualize its distribution between "cell surface, as well as nuclear and mitochondrial membranes" . These techniques have revealed that ZIP9 "participates in the zinc ions efflux out of the secretory compartments" while also functioning as a membrane androgen receptor, enabling researchers to dissect compartment-specific roles.

How are SLC39A9/ZIP9 antibodies being utilized in cancer research?

SLC39A9/ZIP9 antibodies have become valuable tools in cancer research, particularly for breast and prostate cancer studies. Immunohistochemical analysis using these antibodies has revealed that "ZIP9 is up-regulated in malignant breast and prostate tissues, suggesting that it is a potential therapeutic target" . This finding positions ZIP9 as a potential biomarker and therapeutic target. Research employing ZIP9 antibodies in cellular models has demonstrated its role in mediating "testosterone induction of apoptosis" in cancer cell lines. Mechanistic studies combining ZIP9 immunodetection with signaling pathway analysis have elucidated how it "mediates testosterone-induced apoptosis via MAPK- and zinc-dependent pathways" in triple-negative human breast cancer MDA-MB-468 cells and nAR-negative PC-3 human prostate cells. These investigations highlight how ZIP9 antibodies facilitate research into both diagnostic applications and therapeutic mechanisms, potentially leading to novel cancer treatment strategies targeting this dual-function protein.

Why might Western blot results with SLC39A9/ZIP9 antibodies show discrepancies in molecular weight?

Western blot analyses of SLC39A9/ZIP9 frequently reveal discrepancies between the calculated molecular weight (approximately 32 kDa) and observed weights ranging from 25 kDa to 68 kDa . These variations stem from multiple factors researchers should consider when interpreting results. First, post-translational modifications—particularly glycosylation of transmembrane proteins like ZIP9—can significantly increase apparent molecular weight. Second, the protein's high hydrophobicity with eight transmembrane domains may cause anomalous migration in SDS-PAGE. Third, different antibodies targeting distinct epitopes may recognize specific protein isoforms or conformational states. For example, Proteintech's antibody typically detects a 25 kDa band , while Boster's antibody observes a 68 kDa band . Fourth, sample preparation conditions, including lysis buffer composition and heating temperature, can affect protein denaturation and detection. Finally, endogenous proteolytic processing may generate fragments detected by epitope-specific antibodies. Researchers should validate observed bands through positive controls, including ZIP9 overexpression lysates, as demonstrated with Abcam's antibody .

What controls are essential when performing immunohistochemistry with SLC39A9/ZIP9 antibodies?

Rigorous immunohistochemistry experiments with SLC39A9/ZIP9 antibodies require comprehensive controls to ensure valid interpretations. Positive tissue controls should include samples with established ZIP9 expression; thyroid tissue has been validated to show strong ZIP9 expression, while pancreatic tissue demonstrates lower expression levels, serving as a relative negative control . Antibody validation through titration is critical—recommended dilutions range from 1:50 to 1:500 depending on the specific antibody and detection system . Antigen retrieval method optimization significantly impacts results; Proteintech recommends "antigen retrieval with TE buffer pH 9.0; alternatively, antigen retrieval may be performed with citrate buffer pH 6.0" . Negative controls should include both primary antibody omission and isotype controls. For definitive specificity validation, peptide competition, where the immunizing peptide blocks antibody binding, provides compelling evidence of signal specificity. Finally, comparative analysis of serial sections stained with multiple ZIP9 antibodies targeting different epitopes can strengthen confidence in observed staining patterns.

How should researchers address conflicting results from different SLC39A9/ZIP9 antibodies?

When confronted with conflicting results from different SLC39A9/ZIP9 antibodies, researchers should implement a systematic resolution strategy. First, compare the immunogens used to generate each antibody—Abcam's antibody targets amino acids 100-200 , while Boster's targets amino acids 70-120 —as epitope location can affect detection under different experimental conditions. Second, evaluate each antibody's validation data, including tissues with established expression patterns and overexpression systems. Third, employ complementary detection methods: if Western blot results conflict, confirm with immunofluorescence or immunoprecipitation. Fourth, consider experimental variables such as sample preparation techniques, as membrane proteins like ZIP9 are particularly sensitive to detergent selection and denaturation conditions. Fifth, verify results with genetic approaches using ZIP9 knockout or knockdown systems as definitive specificity controls. Finally, acknowledge potential biological variables—ZIP9's dual function as zinc transporter and androgen receptor may result in context-dependent conformational states or protein modifications that affect epitope accessibility, leading to apparently contradictory detection patterns across different experimental systems.

What recent advances have emerged regarding SLC39A9/ZIP9's role in non-classical androgen signaling?

Recent research has revealed sophisticated mechanisms underlying ZIP9's function in non-classical androgen signaling across diverse cell types. Studies employing ZIP9 antibodies have demonstrated that it "functions as a membrane androgen receptor that mediates, through a G protein, the non-classical androgen signaling pathway, characterized by the activation of MAPK3/MAPK1 (Erk1/2) and transcription factors CREB1 or ATF1" . This signaling cascade contributes to crucial physiological processes including "CLDN1 and CLDN5 expression and tight junction formation between adjacent Sertoli cells" . In vascular endothelial cells, ZIP9 mediates "androgen-induced vascular endothelial cell proliferation through activation of an inhibitory G protein leading to the AKT1 and MAPK3/MAPK1 (Erk1/2) activation" . Furthermore, investigations in spermatogenic cell lines have established that "the non-classical signaling pathway of testosterone was mediated by the ZIP9 zinc transporter" . Notably, research using cell lines lacking classical androgen receptors demonstrated that "ZIP9-mediated phosphorylation of Erk1/2, CREB, or ATF-1, as well as expression of claudin-5 and zonula occludens-1 by testosterone, can be completely antagonized by bicalutamide" , revealing potential therapeutic implications.

How might SLC39A9/ZIP9 antibodies contribute to therapeutic target validation in cancer research?

SLC39A9/ZIP9 antibodies are proving invaluable for therapeutic target validation in cancer research through multiple complementary approaches. Immunohistochemical studies have revealed that "ZIP9 is up-regulated in malignant breast and prostate tissues" , establishing its potential as both a diagnostic biomarker and therapeutic target. Mechanistic investigations combining ZIP9 antibody detection with functional assays have elucidated its role in "testosterone-induced apoptosis via MAPK- and zinc-dependent pathways" in cancer cells. This dual functionality presents unique therapeutic opportunities, as targeting ZIP9 could potentially disrupt both zinc homeostasis and androgen signaling in cancer cells. Immunoprecipitation studies with ZIP9 antibodies can identify interaction partners, enabling the development of small molecules disrupting specific protein-protein interactions. Additionally, ZIP9 antibodies can validate target engagement in drug discovery pipelines through competitive binding assays. The observation that ZIP9 mediates apoptosis specifically in cancer cells suggests potential therapeutic windows, which can be further explored using antibody-based tissue screening to identify cancer types with ZIP9 overexpression, potentially guiding patient stratification for targeted therapies.

What methodological advancements are improving the detection and functional characterization of SLC39A9/ZIP9?

Methodological advancements are significantly enhancing the precision and scope of SLC39A9/ZIP9 detection and functional characterization. Super-resolution microscopy techniques combined with ZIP9 antibodies now enable nanoscale visualization of its subcellular distribution across "plasma membrane and endoplasmic reticulum" as well as "cell surface, nuclear and mitochondrial membranes" . Multiplexed immunofluorescence approaches allow simultaneous detection of ZIP9 alongside zinc transporters and signaling pathway components, providing contextual insights into its functional interactions. CRISPR-Cas9 gene editing creates precise knockout models for definitive antibody validation and functional studies. For functional investigations, zinc-specific fluorescent sensors combined with ZIP9 immunodetection enable spatiotemporal correlation between protein localization and zinc transport activity. Proximity labeling techniques using ZIP9 antibodies facilitate unbiased identification of protein interaction networks in native cellular environments. Single-cell analyses combining ZIP9 detection with transcriptomics or proteomics can reveal cell type-specific functions and expression patterns. These methodological innovations collectively enhance our ability to dissect ZIP9's dual functionality as both zinc transporter and androgen receptor, potentially leading to novel therapeutic strategies targeting this multifunctional protein.